BeiGene, Inc.

BeiGene, Inc. is a global biotechnology company focused on discovering and developing innovative medicines for the treatment of cancer. Founded in 2010, the company has rapidly grown to become a leader in the biopharmaceutical industry, with a commitment to advancing the science of oncology.

At BeiGene, we are dedicated to improving patient outcomes through our robust pipeline of targeted therapies and immuno-oncology treatments. Our research and development efforts are driven by a team of world-class scientists and clinicians who are passionate about making a difference in the lives of patients.

We have established a strong presence in both the United States and China, allowing us to leverage diverse resources and expertise. Our state-of-the-art facilities are equipped with cutting-edge technology to support our drug discovery and development processes.

Core Activities:

• Research and Development: We invest heavily in R&D to discover new therapeutic options for patients.
• Clinical Trials: Our clinical trials are designed to evaluate the safety and efficacy of our drug candidates.
• Commercialisation: We aim to bring our innovative therapies to market, ensuring they are accessible to patients worldwide.

Our vision is to transform the treatment landscape for cancer patients globally. We believe that by harnessing the power of science and innovation, we can create a brighter future for those affected by cancer.

As we continue to grow, we remain committed to our core values of integrity, collaboration, and excellence. At BeiGene, we understand that our success is measured by the impact we have on patients’ lives.